Repros Therapeutics submits Androxal revised indication statement to the FDA

Repros Therapeutics Inc. today announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA’s Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state.

Related posts:

1. Repros Therapeutics receives further clarification on the Full Clinical Hold status of Proellex
2. Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial
3. Halozyme Therapeutics to present its product development pipeline